Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
pamidronate disodium · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| filgrastim | BIOLOGICAL | - |
| anastrozole | DRUG | - |
| carboplatin | DRUG | - |
| cisplatin | DRUG | - |
| cyclophosphamide | DRUG | - |
| docetaxel | DRUG | - |
| doxorubicin hydrochloride | DRUG | - |
| etoposide | DRUG | - |
| pamidronate disodium | DRUG | - |
| thiotepa | DRUG | - |
| peripheral blood stem cell transplantation | PROCEDURE | - |
DISEASE CHARACTERISTICS: Histologically confirmed epithelial carcinoma of the breast Metastatic disease including ipsilateral supraclavicular lymph nodes and the chest wall (no axillary nodes) Measurable or evaluable (bone only) disease on exam or radiography No apocrine, adenocystic, squamous cell ...
Top 20 of 92 competitors
Pamidronate disodium is a small molecule being studied for use in breast cancer, specifically in women with metastatic breast cancer. It is being investigated as part of a combination chemotherapy regimen followed by peripheral stem cell transplantation. The drug is currently in Phase 2 clinical development.
Pamidronate disodium is a bisphosphonate that targets bone resorption by inhibiting osteoclast activity. In the context of breast cancer, it is being studied for its potential role in managing bone metastases. The drug's mechanism involves reducing bone turnover and potentially preventing skeletal-related events.
Pamidronate disodium is being developed by Meridian Bioscience Inc, which trades under the ticker VIVO. The company is conducting clinical research on this drug for the treatment of breast cancer. As of the latest data, the drug is in Phase 2 development.
Pamidronate disodium is in Phase 2 clinical development for breast cancer. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The drug is being studied in a completed Phase 2 trial for metastatic breast cancer.
Pamidronate disodium has been studied in one clinical trial, NCT00004906, titled 'Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer.' This Phase 2 trial was completed in the United States and enrolled female patients aged 18 years and older.
Pamidronate disodium is the disodium salt form of pamidronate, a bisphosphonate medication. While the data provided does not list alternative names, pamidronate disodium is commonly known as pamidronate in clinical contexts. The drug is being investigated for its role in breast cancer treatment.